Thevax Genetics Vaccine Co., Ltd.

Yi-Tsui Chiu

Chia-Mao Wu

Jiun-Ming Wu

Kuan-Ming Chen

Yi-Chia Lin

Kung-Lung Lee

Chia-Hao Kang

Fu-Hsien Chiang

Cheng-Yung Chang

Wei-Lun Chang

Hsiang-Kai Lin

Chia-Kuan Peng

Wei-Hsiang Lin

Yin-Ching Lin

Hsien-Kai Chuang

Fu-Tan Hsieh

A fusion protein for use as a hepatitis B therapeutic vaccine is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen comprising a hepatitis B virus X protein deletion mutant that lacks amino acids (aa) at least from as 21 to as 50. The protein transduction domain is a fusion polypeptide comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide. The APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen is located at the C-terminus of the protein transduction domain.

Hepatitis B therapeutic vaccines

Vaccine compositions for use in inducing enhanced antigen-specific T cell-mediated immune responses in a subject in need thereof are disclosed. The composition comprises (a) a therapeutically effective amount of an immunogenic protein comprising at least an antigen of a pathogen; (b) a saponin-base adjuvant selected from the group consisting of GPI-0100, Quil A, QS-21; and (c) a Toll-like receptor (TLR) agonist adjuvant selected from the group consisting of monophosphoryl lipid A (MPL), and CpG1826.

Vaccine composition comprising an immunogenic protein and combination adjuvants for use in eliciting antigen-specific T-cell responses

Growing community of inventors

Hsinchu County, Taiwan

Yi-Tsui Chiu